Phase I study of cellular therapy using expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients.
作者信息
Tanaka Junji, Tanaka Norina, Wang Yan-Hua, Mitsuhashi Kenjiro, Ryuzaki Michiko, Iizuka Yuki, Watanabe Aya, Ishiyama Midori, Shinohara Akihito, Kazama Hiroshi, Hagiwara Shotaro, Yoshinaga Kentaro, Kougen Yumi, Kobayashi Hirohito, Kanno Hitoshi, Shiseki Masayuki
机构信息
Department of Hematology
Department of Hematology.
出版信息
Haematologica. 2020 Apr;105(4):e190-e193. doi: 10.3324/haematol.2019.226696. Epub 2019 Aug 8.
Abstract
摘要
相似文献
1
Phase I study of cellular therapy using expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients.采用自体外周血单个核细胞来源的扩增自然杀伤细胞联合含利妥昔单抗化疗对复发的CD20阳性恶性淋巴瘤患者进行细胞治疗的I期研究。
Haematologica. 2020 Apr;105(4):e190-e193. doi: 10.3324/haematol.2019.226696. Epub 2019 Aug 8.
2
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression.体外扩增的淋巴因子激活的杀伤细胞和利妥昔单抗联合维持治疗滤泡淋巴瘤患者安全有效，可能延缓疾病进展。
Br J Haematol. 2020 Jun;189(6):1064-1073. doi: 10.1111/bjh.16474. Epub 2020 Mar 4.
3
Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.
Clin Lymphoma. 2002 Sep;3(2):111-6. doi: 10.3816/clm.2002.n.017.
4
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma.一项前瞻性临床试验评估利妥昔单抗联合普乐沙福作为淋巴瘤患者动员方案的安全性和有效性。
Transfusion. 2013 Jan;53(1):76-84. doi: 10.1111/j.1537-2995.2012.03719.x. Epub 2012 May 25.
5
6
7
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.含抗CD20抗体方案治疗复发或难治性慢性淋巴细胞白血病、弥漫性大B细胞淋巴瘤或滤泡性淋巴瘤患者的循证综述
Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):508-518.e14. doi: 10.1016/j.clml.2018.05.009. Epub 2018 May 23.
8
The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.抗CD20抗体利妥昔单抗可增强抗CD19免疫毒素针对人B细胞淋巴瘤的免疫特异性治疗效果。
Br J Haematol. 2006 Jul;134(2):157-70. doi: 10.1111/j.1365-2141.2006.06155.x. Epub 2006 Jun 12.
9
Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.利妥昔单抗-环磷酰胺、长春新碱、阿霉素、泼尼松、依托泊苷方案，一种用于复发、难治或转化型B细胞淋巴瘤的有效挽救疗法：一项II期研究结果
Ann Oncol. 2004 Mar;15(3):511-6. doi: 10.1093/annonc/mdh093.
引用本文的文献
1
Cytokines in Focus: IL-2 and IL-15 in NK Adoptive Cell Cancer Immunotherapy.聚焦细胞因子：自然杀伤细胞过继性细胞癌症免疫疗法中的白细胞介素-2和白细胞介素-15
Immune Netw. 2025 Apr 9;25(2):e17. doi: 10.4110/in.2025.25.e17. eCollection 2025 Apr.
2
Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective.利用自然杀伤细胞治疗难治性/复发性非霍奇金淋巴瘤：生物学作用、临床试验及未来展望
Biomark Res. 2024 Jul 17;12(1):66. doi: 10.1186/s40364-024-00610-z.
3
Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes.依洛珠单抗通过上调多个 NK 细胞增强基因增强 CD16 非依赖性 NK 细胞对骨髓瘤细胞的细胞毒性。
J Immunol Res. 2024 Feb 27;2024:1429879. doi: 10.1155/2024/1429879. eCollection 2024.
4
Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.增强自然杀伤细胞的功能以克服癌症对基于 NK 细胞治疗的耐药性，并增强基于抗体的免疫疗法。
Front Immunol. 2023 Nov 24;14:1275904. doi: 10.3389/fimmu.2023.1275904. eCollection 2023.
5
Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.绘制通往实体瘤的杀伤性路线：在肿瘤微环境中招募和激活自然杀伤细胞的策略。
Front Immunol. 2023 Nov 8;14:1286750. doi: 10.3389/fimmu.2023.1286750. eCollection 2023.
6
Facing challenges with hope: universal immune cells for hematologic malignancies.满怀希望应对挑战：用于血液系统恶性肿瘤的通用免疫细胞。
Cancer Biol Med. 2023 May 4;20(4):229-47. doi: 10.20892/j.issn.2095-3941.2022.0759.
7
The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL).自然杀伤细胞免疫疗法治疗 B 细胞非霍奇金淋巴瘤（B 细胞 NHL）的未来。
Curr Treat Options Oncol. 2022 Mar;23(3):381-403. doi: 10.1007/s11864-021-00932-2. Epub 2022 Mar 8.
8
Natural Killer Cell-Mediated Immunotherapy for Leukemia.自然杀伤细胞介导的白血病免疫疗法。
Cancers (Basel). 2022 Feb 8;14(3):843. doi: 10.3390/cancers14030843.
9
The promise and perils of immunotherapy.免疫疗法的前景与挑战。
Blood Adv. 2021 Sep 28;5(18):3709-3725. doi: 10.1182/bloodadvances.2021004453C.
10
New Orders to an Old Soldier: Optimizing NK Cells for Adoptive Immunotherapy in Hematology.给一名老兵的新指令：优化自然杀伤细胞用于血液学中的过继性免疫治疗
Biomedicines. 2021 Sep 11;9(9):1201. doi: 10.3390/biomedicines9091201.
本文引用的文献
1
Challenges of NK cell-based immunotherapy in the new era.新时代基于自然杀伤细胞的免疫治疗面临的挑战。
Front Med. 2018 Aug;12(4):440-450. doi: 10.1007/s11684-018-0653-9. Epub 2018 Jul 25.
2
Current strategies exploiting NK-cell therapy to treat haematologic malignancies.利用自然杀伤细胞疗法治疗血液系统恶性肿瘤的当前策略。
Int J Immunogenet. 2018 Jul 16. doi: 10.1111/iji.12387.
3
Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.激活 NK 细胞以预防造血干细胞移植后复发并诱导缓解的策略。
Blood. 2018 Mar 8;131(10):1053-1062. doi: 10.1182/blood-2017-08-752170. Epub 2018 Jan 22.
4
Targeting natural killer cells in cancer immunotherapy.在癌症免疫疗法中靶向自然杀伤细胞。
Nat Immunol. 2016 Aug 19;17(9):1025-36. doi: 10.1038/ni.3518.
5
Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.人自然杀伤细胞在体外扩增后维持许可状态，并受到杀伤细胞免疫球蛋白样受体（KIR）和KIR配体的抑制。
Cancer Immunol Immunother. 2016 Sep;65(9):1047-59. doi: 10.1007/s00262-016-1864-z. Epub 2016 Jul 8.
6
Natural killer cells in the treatment of high-risk acute leukaemia.自然杀伤细胞在高危急性白血病治疗中的应用。
Semin Immunol. 2014 Apr;26(2):173-9. doi: 10.1016/j.smim.2014.02.004. Epub 2014 Mar 5.
7
GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.GMP 合规的、大规模扩增的同种异体自然杀伤细胞在体外和体内对癌细胞具有强大的细胞溶解活性。
PLoS One. 2013;8(1):e53611. doi: 10.1371/journal.pone.0053611. Epub 2013 Jan 11.
8
Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells.体外扩增自然杀伤细胞与单克隆抗体药物联合对癌细胞的协同细胞毒性。
Int Immunopharmacol. 2012 Dec;14(4):593-605. doi: 10.1016/j.intimp.2012.09.014. Epub 2012 Oct 9.
9
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.未经许可的自然杀伤细胞在抗 GD2 抗体治疗后靶向神经母细胞瘤。
J Clin Invest. 2012 Sep;122(9):3260-70. doi: 10.1172/JCI62749. Epub 2012 Aug 6.
10
Dasatinib enhances the expansion of CD56+CD3- NK cells from cord blood.达沙替尼可增强脐血中CD56+CD3-自然杀伤细胞的扩增。
Blood. 2012 Jun 21;119(25):6175-6. doi: 10.1182/blood-2012-03-416800.
Zotero 插件